1. Home
  2. ERAS vs MYE Comparison

ERAS vs MYE Comparison

Compare ERAS & MYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ERAS
  • MYE
  • Stock Information
  • Founded
  • ERAS 2018
  • MYE 1933
  • Country
  • ERAS United States
  • MYE United States
  • Employees
  • ERAS N/A
  • MYE N/A
  • Industry
  • ERAS Biotechnology: Pharmaceutical Preparations
  • MYE Auto Parts:O.E.M.
  • Sector
  • ERAS Health Care
  • MYE Consumer Discretionary
  • Exchange
  • ERAS Nasdaq
  • MYE Nasdaq
  • Market Cap
  • ERAS 396.6M
  • MYE 352.8M
  • IPO Year
  • ERAS 2021
  • MYE N/A
  • Fundamental
  • Price
  • ERAS $1.43
  • MYE $12.08
  • Analyst Decision
  • ERAS Strong Buy
  • MYE Hold
  • Analyst Count
  • ERAS 6
  • MYE 1
  • Target Price
  • ERAS $4.83
  • MYE N/A
  • AVG Volume (30 Days)
  • ERAS 1.5M
  • MYE 269.0K
  • Earning Date
  • ERAS 05-20-2025
  • MYE 05-01-2025
  • Dividend Yield
  • ERAS N/A
  • MYE 4.49%
  • EPS Growth
  • ERAS N/A
  • MYE N/A
  • EPS
  • ERAS N/A
  • MYE 0.28
  • Revenue
  • ERAS N/A
  • MYE $835,929,000.00
  • Revenue This Year
  • ERAS N/A
  • MYE $2.46
  • Revenue Next Year
  • ERAS N/A
  • MYE $2.72
  • P/E Ratio
  • ERAS N/A
  • MYE $41.37
  • Revenue Growth
  • ERAS N/A
  • MYE 3.92
  • 52 Week Low
  • ERAS $1.01
  • MYE $9.06
  • 52 Week High
  • ERAS $3.45
  • MYE $23.05
  • Technical
  • Relative Strength Index (RSI)
  • ERAS 52.92
  • MYE 66.24
  • Support Level
  • ERAS $1.37
  • MYE $11.39
  • Resistance Level
  • ERAS $1.61
  • MYE $12.21
  • Average True Range (ATR)
  • ERAS 0.14
  • MYE 0.48
  • MACD
  • ERAS 0.00
  • MYE 0.27
  • Stochastic Oscillator
  • ERAS 53.09
  • MYE 96.35

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

About MYE Myers Industries Inc.

Myers Industries Inc designs, manufactures, and markets a variety of plastic, metal, and rubber products, including a broad selection of plastic reusable containers, pallets, small parts bins, bulk shipping containers, storage and organization products, OEM parts, custom plastic products, consumer fuel containers and tanks for water, fuel and waste handling. It operates through the following segments: The Material Handling segment manufactures a selection of durable plastic reusable products that are used repeatedly during the course of their service life. The Distribution segment is engaged in the distribution of equipment, tools, and supplies used for tire servicing and automotive under-vehicle repair, etc. It generates the majority of its revenue from the Material Handling segment.

Share on Social Networks: